Yassine, Farah
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Tsalantsanis, Athanasios
Roy, Vivek http://orcid.org/0000-0002-5950-4620
Zubair, Abba C. http://orcid.org/0000-0003-4827-4740
Murthy, Hemant S.
Ayala, Ernesto
Iqbal, Madiha http://orcid.org/0000-0001-6752-5440
Sher, Taimur
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Parrondo, Ricardo D. http://orcid.org/0000-0002-9314-9933
Article History
Received: 7 February 2023
Revised: 4 June 2023
Accepted: 21 June 2023
First Online: 21 July 2023
Competing interests
: HSM: CRISPR Therapeutics: consultancy, research funding. SA: Janssen: consultancy, research funding; Medimmune: research funding; Beigene: consultancy; GSK: consultancy, research funding; Xencor: research funding; AbbVie: consultancy; Sanofi: consultancy; Karyopharm: consultancy; Ascentage: research funding; Pharmacyclics: consultancy, research funding; Amgen: consultancy, research funding; Cellectar: research funding; Genentech: consultancy; BMS: consultancy, research funding; Takeda: consultancy. MAK-D: Grant/research with Novartis and Bristol Myers Squibb. RDP: Bristol Myers Squibb Foundation: research funding; Sanofi Aventis: advisory board. All other authors report no conflict of interest.